Showing 351-360 of 370 results for "".
- Live Cosmetic Surgery Workshop This Septemberhttps://practicaldermatology.com/news/20130812-live_cosmetic_surgery_workshop_this_september/2459480/Dr. Joe Niamtu, III will present the 2013 Ultimate Facial Rejuvenation Live Cosmetic Surgery Workshop September 20-22. The course will include lectures and live surgeries on:facelift and facial liposuction, browlift, eyelid surgery, facial implants, laser resurfacing, chemical peels, fillers, mole …
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis…
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted i…
- Anterios CEO to Present at Healthcare Conferencehttps://practicaldermatology.com/news/20130429-anterios_ceo_to_present_at_healthcare_conference/2459558/CEO and Founder of Anterios, Inc., Jon Edelson, MD, will be presenting at Needham & Company's 12th Annual Healthcare Conference in New York City on April 30, 2013. In other company news, Anterios also recently received an $8.5 million round of financing for the development and progress of their top…
- Investigational Melanoma Agent Meets Endpoint in Phase 3 Trialhttps://practicaldermatology.com/news/20130320-investigational_melanoma_agent_meets_endpoint_in_phase_3_trial/2459582/New Phase 3 trial data found that Amgen's investigational melanoma agent talimogene laherparepvec met its primary endpoint of durable response rate for the treatment of unresected stage IIIB, IIIC, or IV melanoma. Researchers observed a statistically significant difference of 16 percent in DRR in p…
- Kythera Biopharmaceuticals Appoints New CMOhttps://practicaldermatology.com/news/20130318-kythera_biopharmaceuticals_appoints_new_cmo/2459587/Frederick Beddingfield, III, MD, PhD has been appointed Chief Medical Officer of Kythera Biopharmaceuticals, Inc. Dr. Beddingfield is a board-certified dermatologist who joins the company from Allergan, Inc., where he most recently held the role of Vice President and Therapeutic Area Head, Dermatol…
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment…
- Modern Aesthetics Launches from Bryn Mawr Communicationshttps://practicaldermatology.com/news/20130228-modern_aesthetics_launches_from_bryn_mawr_communications/2459603/The debut issue of Modern Aesthetics (www.modernaesthetics.com), a publication dedicated to coverage of minimally invasive cosmetic procedures and targeting Plastic Surgeons, Facial Plastic Surgeons, Oculoplastic Surgeons, and Dermatologists, has been released by Bryn Mawr Communications III, LLC. …
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite trea…
- Brickell Biotech Announces Funding for Development of Novel Dermatology Treatmentshttps://practicaldermatology.com/news/20130226-brickell_biotech_announces_funding_for_development_of_novel_dermatology_treatments/2459608/Brickell Biotech, Inc., a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, announced a $7 million Series B financing round to fund new chemical entities in dermatology for indications including acne, atopic dermatit…